Liquid biopsy for lung cancer screening: Usefulness of circulating tumor cells and other circulating blood biomarkers

2020 ◽  
Author(s):  
Paul Hofman
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Lung Cancer Screening ◽  
Blood Biomarkers

Circulating Tumor Cells as a Potential Biomarker for Lung Cancer Screening: Results of the AIR Study

2019 ◽  
Author(s):  
Charles-Hugo Marquette ◽  
Jacques Boutros ◽  
Jonathan Benzaquen ◽  
Marion Ferreira ◽  
Jean Pastre ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Lung Cancer Screening ◽  
Potential Biomarker

scholarly journals Thermal liquid biopsy as a valuable tool in lung cancer screening programs

2019 ◽  
Vol 30 ◽  
pp. v579-v580
Author(s):  
A. Rodrigo ◽  
S. Vega ◽  
J. Ojeda Cabrera ◽  
O. Sanchez-Gracia ◽  
A. Callejo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Liquid Biopsy ◽  
Lung Cancer Screening ◽  
Screening Programs

Abstract 3329: Lung cancer screening initiative and identification of novel blood biomarkers for early detection of lung cancer

2019 ◽  
Author(s):  
Adijan Kuckovic ◽  
Joseph Berei ◽  
Shylendra Sreenivasappa ◽  
Joseph Ross ◽  
Sandra Martell ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Early Detection ◽  
Lung Cancer Screening ◽  
Blood Biomarkers

scholarly journals Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges

Cancers ◽  
2019 ◽  
Vol 12 (1) ◽  
pp. 17 ◽  
Author(s):  
Erika Rijavec ◽  
Simona Coco ◽  
Carlo Genova ◽  
Giovanni Rossi ◽  
Luca Longo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cell Lung Cancer ◽  
Liquid Biopsy ◽  
Tumor Biology ◽  
Small Cell ◽  
Small Cell Lung ◽  
Screening Programs

Non-small cell lung cancer is one leading cause of death worldwide, and patients would greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged as novel approaches for more tailored treatments, repeated assessments of the tumor biology have become pivotal to drive clinical decisions. Currently, tumor tissue biopsy is the gold standard to investigate potentially actionable biomarkers, but this procedure is invasive and may prove inadequate to represent the whole malignancy. In this regard, liquid biopsy represents a minimally invasive and more comprehensive option for early detection and investigation of this tumor. Today, cell-free DNA is the only approved circulating marker to select patients for a targeted therapy. Conversely, the other tumor-derived markers (i.e., circulating tumor cells, miRNAs, exosomes, and tumor educated platelets) are still at a pre-clinical phase, although they show promising results for their application in screening programs or as prognostic/predictive biomarkers. The main challenges for their clinical translation are the lack of reliable cutoffs and, especially for miRNAs, the great variability among the studies. Moreover, no established tool has been approved for circulating tumor cells and exosome isolation. Finally, large prospective clinical trials are mandatory to provide evidence of their clinical utility.

scholarly journals Required Evidence for Clinical Applications of Liquid Biopsy Using Especially CTCs in Lung Cancer

2020 ◽  
Vol 10 (11) ◽  
pp. 3704
Author(s):  
Menno Tamminga ◽  
Harry J.M. Groen
Keyword(s):  
Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Patient Characteristics ◽  
Clinical Applications ◽  
Liquid Biopsies ◽  
Improved Outcomes ◽  
Tumor Material

As therapies have become more and more dependent on tumor as well as patient characteristics, obtaining tumor material has become of great importance. Liquid biopsies hold much potential as shown by a large amount of evidence across several studies. Clinical applications for circulating tumor cells (CTCs) are unfortunately still lacking. In part this is due to a lack of studies comparing liquid biopsies to conventional diagnostics and response measurements as well as studies showing that liquid biopsies can be used to switch therapies leading to improved outcomes. However, liquid biopsies using ctDNA for specific markers such as EGFR, ALK, ROS1 or RET have clinical applications because specific drugs are available.

Abstract 3329: Lung cancer screening initiative and identification of novel blood biomarkers for early detection of lung cancer

2019 ◽  
Author(s):  
Adijan Kuckovic ◽  
Joseph Berei ◽  
Shylendra Sreenivasappa ◽  
Joseph Ross ◽  
Sandra Martell ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Early Detection ◽  
Lung Cancer Screening ◽  
Blood Biomarkers

scholarly journals P1.19 Lung Cancer Screening Initiative and Identification of Novel Blood Biomarkers for Early Detection of Lung Cancer

2019 ◽  
Vol 14 (11) ◽  
pp. S1147-S1148
Author(s):  
S. Deb ◽  
A. Kuckovic ◽  
A. Anderson ◽  
J. Berei ◽  
S. Sreenivasappa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Early Detection ◽  
Lung Cancer Screening ◽  
Blood Biomarkers
Sign in / Sign up

Export Citation Format

Share Document